$CORT
Corcept Therapeutics Inc Stock $cort

$cort Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000162828023035988 Filed on November 01, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$135.4M	$123.6M
YoY Change	31.39%	21.5%
Cost Of Revenue	$1.877M	$1.645M
YoY Change	26.82%	22.85%
Gross Profit	$133.5M	$122.0M
YoY Change	31.46%	21.48%
Gross Profit Margin	98.61%	98.67%
Selling, General & Admin	$47.15M	$45.26M
YoY Change	11.41%	28.72%
% of Gross Profit	35.31%	37.11%
Research & Development	$54.71M	$45.52M
YoY Change	48.85%	36.72%
% of Gross Profit	40.97%	37.32%
Depreciation & Amortization	$542.0K	$100.0K
YoY Change	196.17%	-48.72%
% of Gross Profit	0.41%	0.08%
Operating Expenses	$101.9M	$90.78M
YoY Change	28.81%	32.61%
Operating Profit	$31.67M	$31.18M
YoY Change	40.76%	-2.37%
Interest Expense	$5.140M	$5.200M
YoY Change	189.25%	385.98%
% of Operating Profit	16.23%	16.68%
Other Income/Expense, Net		$5.208M
YoY Change		386.73%
Pretax Income	$36.81M	$36.39M
YoY Change	51.63%	10.24%
Income Tax	$5.454M	$5.000M
% Of Pretax Income	14.82%	13.74%
Net Earnings	$31.36M	$31.38M
YoY Change	88.87%	-9.33%
Net Earnings / Revenue	23.16%	25.39%
Basic Earnings Per Share		$0.31
Diluted Earnings Per Share	$0.28	$0.28
COMMON SHARES
Basic Shares Outstanding	103.1M shares	102.5M shares
Diluted Shares Outstanding		111.1M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$368.2M	$355.2M
YoY Change	-14.7%	-10.36%
Cash & Equivalents	$135.6M	$111.8M
Short-Term Investments	$232.7M	$243.4M
Other Short-Term Assets	$41.56M	$34.20M
YoY Change	36.61%	65.38%
Inventory	$7.730M	$7.513M
Prepaid Expenses	$4.319M
Receivables	$41.12M	$34.63M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$458.6M	$431.5M
YoY Change	-8.14%	-4.61%
LONG-TERM ASSETS
Property, Plant & Equipment	$195.0K	$302.0K
YoY Change	-69.19%	-62.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$57.18M	$59.60M
YoY Change	1055.77%	1117.57%
Other Assets	$6.541M	$6.540M
YoY Change	29.32%	28.71%
Total Long-Term Assets	$162.9M	$162.5M
YoY Change	93.5%	100.98%
TOTAL ASSETS
Total Short-Term Assets	$458.6M	$431.5M
Total Long-Term Assets	$162.9M	$162.5M
Total Assets	$621.5M	$594.0M
YoY Change	6.53%	11.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.40M	$16.71M
YoY Change	45.26%	104.33%
Accrued Expenses	$51.63M	$69.63M
YoY Change	67.63%	136.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$104.5M	$121.9M
YoY Change	44.16%	129.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$10.31M	$10.50M
YoY Change	13.3%	53.89%
Total Long-Term Liabilities	$10.31M	$10.50M
YoY Change	13.3%	53.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$104.5M	$121.9M
Total Long-Term Liabilities	$10.31M	$10.50M
Total Liabilities	$114.8M	$132.3M
YoY Change	40.72%	120.97%
SHAREHOLDERS EQUITY
Retained Earnings	$402.5M	$371.2M
YoY Change	35.81%	32.66%
Common Stock	$738.5M	$722.5M
YoY Change	563651.91%	11.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$506.7M	$461.7M
YoY Change
Total Liabilities & Shareholders Equity	$621.5M	$594.0M
YoY Change	6.53%	11.4%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	$31.36M	$31.38M
YoY Change	88.87%	-9.33%
Depreciation, Depletion And Amortization	$542.0K	$100.0K
YoY Change	196.17%	-48.72%
Cash From Operating Activities	$5.839M	$53.00M
YoY Change	-82.51%	57.51%
INVESTING ACTIVITIES
Capital Expenditures	$39.00K	$0.00
YoY Change	25.81%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$17.14M	-$109.6M
YoY Change	-199.62%	2369.02%
Cash From Investing Activities	$17.11M	-$109.6M
YoY Change	-199.22%	2188.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	777.0K	-3.900M
YoY Change	-1373.77%	-72.07%
NET CHANGE
Cash From Operating Activities	5.839M	53.00M
Cash From Investing Activities	17.11M	-109.6M
Cash From Financing Activities	777.0K	-3.900M
Net Change In Cash	23.72M	-60.50M
YoY Change	47.47%	-506.12%
FREE CASH FLOW
Cash From Operating Activities	$5.839M	$53.00M
Capital Expenditures	$39.00K	$0.00
Free Cash Flow	$5.800M	$53.00M
YoY Change	-82.61%	55.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	133000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	131000	usd
CY2023Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1645000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1339000	usd
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45517000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33292000	usd
CY2023Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45262000	usd
CY2023Q3	us-gaap	Costs And Expenses CostsAndExpenses	92424000	usd
CY2022Q3	us-gaap	Costs And Expenses CostsAndExpenses	69794000	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	31177000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	31934000	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5208000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1070000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	36385000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	33004000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	34608000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-95000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	74000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-184000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-314000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	31099000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	34368000	usd
	us-gaap	Profit Loss ProfitLoss	74785000	usd
	us-gaap	Profit Loss ProfitLoss	84817000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	35875000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	31921000	usd
	cort	Accretion Expense Income AccretionExpenseIncome	-5933000	usd
	cort	Accretion Expense Income AccretionExpenseIncome	2121000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-25821000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-29438000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1262000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1623000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3569000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1789000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-936000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1074000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5221000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12363000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4783000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	515000	usd
	cort	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	6732000	usd
	cort	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	1329000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	36695000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	1747000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	6414000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1215000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	121152000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	86935000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	139000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	382000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	298846000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	73808000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-97086000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	145428000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8111000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	20819000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77617000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	111800000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50243000	usd
	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	22199000	usd
	cort	Shares Repurchased In Net Settlement Of Cashless Option Exercise SharesRepurchasedInNetSettlementOfCashlessOptionExercise	21975000	usd
	cort	Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability	297000	usd
	cort	Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability	2816000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35163000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5007000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1604000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	31378000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	34608000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	31172000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	31172000	usd
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.30
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102014000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107125000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111099000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116620000	shares
CY2023Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-31000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	23000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	470000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	599000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1373000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1635000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	372793000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	161718000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	258422000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4050000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	3596000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-149489000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-17223000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	45471000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-27374000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66329000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	501842000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6540000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	6359000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10966000	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	716000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	15879000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	529584000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4497000	usd
CY2023Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4823000	usd
CY2023Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	145428000	usd
CY2023Q2	cort	Treasury Stock Value Acquired Excise Tax TreasuryStockValueAcquiredExciseTax	1316000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11374000	usd
CY2023Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	198000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	27528000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	421614000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13950000	usd
CY2023Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	17866000	usd
CY2023Q3	cort	Treasury Stock Value Acquired Excise Tax TreasuryStockValueAcquiredExciseTax	-152000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11660000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	1070000	usd
CY2023Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-279000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	31378000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	461679000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	375806000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6544000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7037000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10825000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1124000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	22797000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	407811000	usd
CY2022Q2	cort	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Vested StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockVested	6597000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	9366000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10662000	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-790000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	27412000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	442326000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12226000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	26187000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10631000	usd
CY2022Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-240000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	34608000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	473364000	usd
	cort	Number Of Series Of Selective Cortisol Modulators NumberOfSeriesOfSelectiveCortisolModulators	4	series
	cort	Number Of Compounds NumberOfCompounds	1000	compound
CY2023Q3	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	8743000	usd
CY2022Q4	cort	Inventory Work In Process Current And Noncurrent InventoryWorkInProcessCurrentAndNoncurrent	7827000	usd
CY2023Q3	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	7522000	usd
CY2022Q4	cort	Inventory Finished Goods Current And Noncurrent InventoryFinishedGoodsCurrentAndNoncurrent	9204000	usd
CY2023Q3	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	16265000	usd
CY2022Q4	cort	Inventory Current Noncurrent InventoryCurrentNoncurrent	17031000	usd
CY2023Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	8752000	usd
CY2022Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	10931000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	7513000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6100000	usd
CY2023Q3	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	30037000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	89000	usd
CY2023Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18424000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15511000	usd
CY2023Q3	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	14546000	usd
CY2022Q4	cort	Accrued Government Rebate Current AccruedGovernmentRebateCurrent	11098000	usd
CY2023Q3	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	2501000	usd
CY2022Q4	cort	Accrued Legal Fees Current AccruedLegalFeesCurrent	2673000	usd
CY2023Q3	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1491000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	434000	usd
CY2023Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	1164000	usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	0	usd
CY2023Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	547000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	211000	usd
CY2023Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	923000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	783000	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	69633000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30799000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	349003000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss	406670000	usd
CY2023Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	1300000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1800000	usd
	cort	Marketable Securities Maximum Maturity Period MarketableSecuritiesMaximumMaturityPeriod	P27M
	cort	Marketable Securities Short Term Maximum Maturity Period MarketableSecuritiesShortTermMaximumMaturityPeriod	P1Y
	cort	Marketable Securities Weighted Average Maturity Period MarketableSecuritiesWeightedAverageMaturityPeriod	P8M
CY2023Q3	cort	Loss Contingency Accrual Other LossContingencyAccrualOther	0	usd
CY2023Q3	cort	Loss Contingency Accrual Provision Other LossContingencyAccrualProvisionOther	0	usd
CY2023Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1800000	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1700000	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	617000	usd
CY2022Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	578000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1774000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1687000	usd
CY2023Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	297000	usd
CY2022Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	297000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2816000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9M
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9M
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.040
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	77000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	155000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	232000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	225000	usd
CY2023Q3	cort	Lessee Short Term Lease Liability To Be Paid Remainder Of Fiscal Year LesseeShortTermLeaseLiabilityToBePaidRemainderOfFiscalYear	500000	usd
CY2023Q3	cort	Lessee Short Term Lease Liability To Be Paid Year One LesseeShortTermLeaseLiabilityToBePaidYearOne	1100000	usd
CY2023Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	44000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	77000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	170000	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	197000	usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	12919000	usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	10631000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	36045000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	32118000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	31172000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	31172000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	34550000	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	34550000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	74353000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	74353000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	84755000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	84755000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102014000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107125000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103933000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106479000	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9085000	shares
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9495000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	8121000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9339000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	111099000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116620000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112054000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115818000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.72
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.80
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.30
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1600000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7100000	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	700000	usd
	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	1800000	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	10400000	usd
CY2023Q3	cort	Unrecognized Tax Benefits That Would Be Offset By A Change In Valuation Allowance UnrecognizedTaxBenefitsThatWouldBeOffsetByAChangeInValuationAllowance	2800000	usd
CY2023Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001628280-23-035988-index-headers.html	Edgar Link	pending
0001628280-23-035988-index.html	Edgar Link	pending
0001628280-23-035988.txt	Edgar Link	pending
0001628280-23-035988-xbrl.zip	Edgar Link	pending
cort-20230930.htm	Edgar Link	pending
cort-20230930.xsd	Edgar Link	pending
cort93023ex311.htm	Edgar Link	pending
cort93023ex312.htm	Edgar Link	pending
cort93023ex321.htm	Edgar Link	pending
cort93023ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cort-20230930_lab.xml	Edgar Link	unprocessable
cort-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cort-20230930_htm.xml	Edgar Link	completed
cort-20230930_cal.xml	Edgar Link	unprocessable
cort-20230930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CORT
Corcept Therapeutics Inc Stock $cort

2023 Q4 Form 10-Q Financial Statement

#000162828023035988 Filed on November 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT Corcept Therapeutics Inc Stock $cort

2023 Q4 Form 10-Q Financial Statement

#000162828023035988 Filed on November 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CORT
Corcept Therapeutics Inc Stock $cort